14. December 2022 Company Augxano and BIT Pharma enter into an Agreement for Commercialization Support in Asia
29. October 2022 Company ASPEN And BIT PHARMA Enter Into An Exclusive Agreement For A Nicardipine-Based Intracerebral Implant
19. October 2022 Pipeline European Medicines Agency Grants PRIME Designation to BIT Pharma’s NicaPlant® for Treatment of Non-traumatic Subarachnoid Haemorrhage in Patients undergoing Surgery.
31. August 2022 Pipeline BIT Pharma Announces the Presentation of NicaPlant® Phase 2 Results at International Conferences
1. July 2022 Pipeline BIT Pharma Announces Positive Phase 2b Study Results for NicaPlant® in Aneurysmal Subarachnoid Heamorrhage patients (aSAH) undergoing aneurysm clipping.
